Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 21NIH 5NETWORK 3FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Estramustine × Clear all
NCT00005847 2023-06-22

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Eastern Cooperative Oncology Group

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

NCT00003614 2023-06-15

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Eastern Cooperative Oncology Group

Phase 2 Completed
Genitourinary

Prostatic Neoplasms

NCT00028769 2013-07-16

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

SWOG Cancer Research Network

Phase 2 Completed
41 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡